*For medical professionals for reference
November 16, 2024, HER2 mutant lung cancer precision diagnosis and treatment summit will be coming, six Geological linkage to explore the future.
HER2 mutation is (NSCLC) clear driving gene mutation. Among the patients in China in China, the HER2 mutation rate About 4%, in the tide of precision medical care, HER2 mutant NSCLCs precise diagnosis and treatment strategy is becoming a global hot spot.In the past, due to the lack of targeted treatment, HER2 mutant NSCLC treatment has always faced challenges.However, with the continuous and in -depth research on HER2 mutation mechanism, coupled with the continuous improvement of biomarkers detection technology, the progress of the development of new drugs, and the innovative improvement of clinical trial design, the current HER2 mutant NSCLC treatment has achieved breakthroughs. Progress, especially the application of HER2 targeted therapy, such as the new ADC drug T-DXD, has brought significant survival benefits to patients with HER2 mutations and HER2 overhauls of late NSCLC.Destiny-lung05 was unveiled at the AACR conference in 2024. The Independent Center Evaluation (ICR) evaluation and confirmed ORR is as high as 58.3%, and the PFS rate of 12 months is 55.1%.And the medium-bit PFS evaluated by the researcher (INV) reached 10.8 months [1] , which verified the treatment benefits of T-DXD in the late NSCLC patients in HER2 mutations in China.Looking forward to the future, the treatment of HER2 mutation NSCLC will continue to move towards precision medical care. It is expected that more innovative drugs and personalized treatment programs will emerge, which will further improve the treatment effect and quality of life of such patients.
On November 16, 2024, a cross -regional academic event will be jointly held with the five major venues of Xiamen, Hangzhou, Nanjing, Beijing, and Tianjin at the main venue of Xian to bring together the top domestic top in China Experts and scholars, explore the precision diagnosis and treatment of HER2 mutant lung cancer.The main venue was Professor of the President of the Conference Professor Hu Yi of the General Hospital of the Peoples Liberation Army , Professor Zhou Cun, Affiliated to Tongji University, Professor Zhou Cun and Professor Zhang Li, the Center of Sun Yat -sen University Leading, Xiamen Branch Presidium Professor He Yuming of Quanzhou First Hospital and Southern Medical University Southern Hospital Professor You Changxuan , Hangzhou Branch Presidium Affiliated to Zhejiang University Medical College Professor Zhou Jianying of First Hospital , Nanjing Branch Presidium Professor Guo Renhua, the First Affiliated Hospital of Nanjing Medical University , South Jinling Hospital of Jingling Hospital of Beijing University School Professor , Professor Jiang Hochun, Anhui Provincial Hospital and Professor Wang Rui, General Hospital of the Eastern Theater , the Presidium of the Beijing Branch Professor Jiao Shunchang of the Peoples Liberation Army General Hospital and Professor Wang Ziping of Peking University Oncology Hospital , the chairman of the Tianjin Branch Professor Wang Yangli of Tianjin Cancer Hospital and Professor Wang Haitao of the Second Hospital of Tianjin Medical University < /Strong> It will be given to the opening speech (*guests are sorted according to the first letters, and the rankings are not distinguished) to start this academic feast together.The meeting will focus on focusing on the progress of the treatment and future exploration of HER2 mutations in the field of NSCLC, and in-depth discussion of the new journey from the treatment dilemma of the past HER2 target to the current leadership of ADC drugs, as well as in the future, led by ADC represented by T-DXD. Below, lung cancer treatment is about to start a new chapter.
This meeting also specially invited Professor Kaline Pereira, chief scientist of the development of lung cancer ADC drugs. In the direction, it aims to build a high -end platform for the participants in depth HER2 mutant lung cancer precision diagnosis and treatment.This is not only a high -level academic exchange event, but also an important opportunity to promote the breakthrough progress of HER2 mutant lung cancer diagnosis and treatment technology.We look forward to gathering you with you on November 16, 2024 to witness and discuss the latest research results and future development trends of HER2 mutant lung cancer diagnosis and treatment, and work together to create a new era of accurate diagnosis and treatment of lung cancer.
Wonderful information is waiting for you
Reference Literature:
[1] cheng y, wu l, fang y, et al. Trastuzumab deruxtecan (T-DXD) in Chinese patients (PTS) with) Mutant Non-Small Cell LUNG CANCER (NSCLC): Primary Analysis from the Phase2 Destiny-LUNG05 (DL-05) TRIAL. 2024 AACR. CT248.
In Providing scientific information to medical people does not represent the viewpoint of this platform
